Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
HOME > REGULATORY
REGULATORY
- MHLW Notifies of Expected Additional Indications for 3 APIs
September 12, 2012
- PAFSC’s 2nd Committee Designates 7 products as Orphan Drugs Including Glioblastoma Treatment Bevacizumab
September 11, 2012
- Chairman Breaks Tie, Votes to Continue Lower House Discussions on Bill to Establish 3rd-Party Organization
September 11, 2012
- MHLW’s FY2013 Budget Request Includes Funding to Set Up Municipal Generic Drug Promotion Councils
September 11, 2012
- PAFSC 2nd Committee Recommends Approval for Novartis’s COPD Drug
September 11, 2012
- DPJ’s Project Team Concerned that Participation in TPP Agreement Could Interfere with Japan’s Industrial Policies
September 10, 2012
- MHLW to Study Overseas Generic Drug Markets to Support Globalization of Domestic Industry
September 10, 2012
- “Some Problems” Found with UMN Pharma’s Cell Culture Method Development Project: MHLW
September 7, 2012
- Labor Standards Bureau Head Junichi Kaneko to Be Appointed Vice Minister of Health; Pension Bureau Head Jun Ebata to Be Transferred to PFSB: MHLW
September 6, 2012
- MHLW to Request 41.1 Bil. Yen in FY2013 Budget for Drug Discovery Support and Other Special Priority Projects
September 6, 2012
- Project to Develop Vaccines for New Influenza Strains Using Chicken Egg Culture Method Receives “A” Grade: MHLW
September 4, 2012
- 3 Generics with 2 APIs Found to Be Non-Compliant in FY2011 Quality Assurance Project: MHLW
September 4, 2012
- PAFSC’s 1st Committee Recommends Approval for Bayer Yakuhin’s AMD Drug
September 3, 2012
- JPWA, NPhA Confirm Further Efforts Needed to Increase Awareness among Members Amid Lag in Distribution Improvements
September 3, 2012
- MHLW to Seek Funds to Enhance Regulatory Consultation under FY2013 “Priority Budget Scheme”
September 3, 2012
- 1,220 Reports of Adverse Events Associated with OTC Drugs Including 24 Deaths Reported in 5 Years: MHLW
August 31, 2012
- DPJ Submits Bill to Form Third-Party Monitoring Organization for Pharmaceutical Affairs
August 30, 2012
- MHLW to Include Creation of Drug Discovery Support Network in FY2013 Draft Budget Request
August 30, 2012
- MHLW Adds Six APIs/10 Products Including Tenelia to NHI Price List
August 29, 2012
- PMDA Eyes World’s First Approval for New Drugs: Chief Executive Kondo
August 28, 2012
ページ
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
Many members of a key reimbursement policy panel on November 10 called on the health ministry to revisit the current listing requirement of at least 25 years for the designation of essential medicines now that annual revisions have been introduced…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…